KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema

businesswire

KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema – NEWSnet – News… as it used to be

More Press Releases

June 26, 2026

Remote Partners with isolved to Unlock Compliant Global Hiring for 200,000+ US Employers

June 26, 2026

Students Help Educate on the Dangers of Distracted Driving Through the 2026 Project Yellow Light Competition

June 26, 2026

Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig

June 26, 2026

KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema

Remote Partners with isolved to Unlock Compliant Global Hiring for 200,000+ US Employers

Students Help Educate on the Dangers of Distracted Driving Through the 2026 Project Yellow Light Competition

Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig

SUBARU ASCENT EARNS TOP JD POWER RANKING IN 2026 US INITIAL QUALITY STUDY